Q32 Bio - About the company
Q32 Bio is a public company based in Cambridge (United States), founded in 2018 by . It operates as a Developer of drugs for treating autoimmune disorders. Q32 Bio has raised $106M in funding from investors like Atlas Venture, Orbimed and Acorn Bioventures. The company has 3200 active competitors, including 1089 funded and 748 that have exited. Its top competitors include companies like Moderna, Jazz Pharmaceuticals and BeiGene.
Company Details
Developer of drugs for treating autoimmune disorders. It is developing drugs for restoring immune homeostasis to treat severe inflammatory and autoimmune diseases. The company has developed drugs such as ADX-914, ADX-097, novel fusion proteins, and therapies to target the innate and adaptive immune systems.
- Website
- Social
- Email ID
- @q32bio.com
Key Metrics
Founded Year
2018
Location
Cambridge, United States
Stage
Public
Total Funding
in 2 rounds
Latest Funding Round
Investors
Ranked
327th among
Employee Count
as on Dec 31, 2023
Similar Companies
Moderna &
Exit Details
Public
Legal entities associated with Q32 Bio
Q32 Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CIN: 82-2439026 United States, Active | Jun 03, 2020 | - | 34 (as on Dec 31, 2023) | - |
Q32 Bio's funding and investors
Q32 Bio has raised a total funding of $106M over 2 rounds. Its first funding round was on May 27, 2020. Its latest funding round was a Series B round on Oct 29, 2020 for $60M. 8 investors participated in its latest round, lead by Orbimed and Acorn Bioventures.
Q32 Bio has 9 institutional investors including Atlas Venture, Orbimed and Acorn Bioventures.
Here is the list of recent funding rounds of Q32 Bio:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Oct 29, 2020 | $60M | Series B | 5698163 | 7186278 | Orbimed, Acorn Bioventures, and |
May 27, 2020 | $46M | Series A | 4764255 | 1510343 | Atlas Venture, Orbimed, and |
Access funding benchmarks and valuations. Sign up today!View details of Q32 Bio's funding rounds and investors
Q32 Bio's founders and board of directors
The founders of Q32 Bio is . is the CEO of Q32 Bio.
Here are the details of Q32 Bio's key team members:
- : Founder & CSO of Q32 Bio.
View details of
Q32 Bio's employee count trend
Q32 Bio has 34 employees as of Dec 23. The total employee count is 21.0% lower than what it was in Dec 22. Here is Q32 Bio's employee count trend over the years:
Uncover Q32 Bio's growth story! Sign up today!
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Q32 Bio's Competitors and alternates
Top competitors of Q32 Bio include Moderna, Jazz Pharmaceuticals and BeiGene. Here is the list of Top 10 competitors of Q32 Bio, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | BB Biotech, Gershon Capital听&补尘辫;听 | 80/100 |
2nd |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | Oak Hill, InterWest Partners听&补尘辫;听 | 80/100 |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | Rock Springs Capital, T. Rowe Price听&补尘辫;听 | 78/100 |
4th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | HBM Partners, Vivo Capital听&补尘辫;听 | 77/100 |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer. | $317M | 73/100 | |
6th |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | BB Biotech, Colt Ventures听&补尘辫;听 | 72/100 |
7th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | 71/100 | |
8th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Ridgeback Capital Management, Roche听&补尘辫;听 | 71/100 |
9th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | BB Biotech, Avoro Capital Advisors听&补尘辫;听 | 71/100 | |
10th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 71/100 | |
327th |  2018, Cambridge (United States), Public | Developer of drugs for treating autoimmune disorders | $106M | Abingworth, Orbimed听&补尘辫;听 | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Q32 Bio's competitors? Click to see the top ones
Q32 Bio's Investments and acquisitions
Q32 Bio has made no investments or acquisitions yet.
Reports related to Q32 Bio
Here is the latest report on Q32 Bio's sector:
View
News related to Q32 Bio
Media has covered Q32 Bio for a total of 7 events in the last 1 year, 7 of them have been about company updates.
鈥�
PR Newswire鈥�Mar 08, 2025鈥�Q32 Bio
鈥�
PR Newswire鈥�Feb 11, 2025鈥�Q32 Bio
鈥�
Clinical Trials Arena鈥�Feb 11, 2025鈥�Q32 Bio
鈥�
Fierce Biotech鈥�Dec 11, 2024鈥�Q32 Bio
鈥�
PR Newswire鈥�Dec 11, 2024鈥�Q32 Bio
鈥�
PR Newswire鈥�Oct 14, 2024鈥�Q32 Bio
鈥�
Seeking Alpha鈥�Jul 01, 2024鈥�Q32 Bio
鈥�
Seeking Alpha鈥�May 09, 2024鈥�Q32 Bio
鈥�
BioSpace鈥�Apr 03, 2024鈥�Q32 Bio
鈥�
Seeking Alpha鈥�Apr 03, 2024鈥�Q32 Bio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Q32 Bio
Explore our recently published companies
- 3D-Green - Ness Ziona based, 2020 founded, Unfunded company
- Newberg - Unfunded company
- ikanksha Software - Pune based, 2011 founded, Unfunded company
- Alzheimer's Drug Discovery - New York City based, 1998 founded, Funding Raised company
- Caspr - 2025 founded, Unfunded company
- Boost Neuroscience - Menlo Park based, 2020 founded, Acquired company
